









Markets
/
Stocks
/
nasdaq-nbix
/

Neurocrine Biosciences Inc

NBIX

143.190USD

+1.230+0.87%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

14.28BMarket Cap

33.36P/E TTM



Neurocrine Biosciences Inc

143.190

+1.230+0.87%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Neurocrine Biosciences Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neurocrine Biosciences Inc's Score

Industry at a Glance

Industry Ranking

12 / 159

Overall Ranking

41 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 29 analysts

Buy

Current Rating

174.057

Target Price

+22.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Neurocrine Biosciences Inc Highlights

StrengthsRisks

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 58.21% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.36B.

Undervalued

The company’s latest PE is 33.27, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 101.15M shares, decreasing 2.55% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 2.37M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 8.69, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 794.90M, representing a year-over-year increase of 27.78%, while its net profit experienced a year-over-year increase of 61.40%.

Score

Industry at a Glance

Previous score

8.69

Change



Financials

7.23

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.83

Key Metrics

Free cash flow

No Data

Neurocrine Biosciences Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 5.24, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 33.27, which is 364.88% below the recent high of 154.68 and 13.56% above the recent low of 28.76.

Score

Industry at a Glance

Previous score

5.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.48, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Neurocrine Biosciences Inc is 175.00, with a high of 203.00 and a low of 142.00.

Score

Industry at a Glance

Previous score

8.48

Change

Support & Resistance

No Data

Analyst Rating

Based on 29 analysts

Buy

Current Rating

174.057

Target Price

+22.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Neurocrine Biosciences Inc

NBIX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 8.93, which is higher than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 150.91 and the support level at 134.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.43

Change

1.5

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.072

Buy

RSI(14)

53.654

Neutral

STOCH(KDJ)(9,3,3)

54.578

Neutral

ATR(14)

4.421

High Vlolatility

CCI(14)

17.938

Neutral

Williams %R

41.478

Buy

TRIX(12,20)

0.094

Sell

StochRSI(14)

97.869

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

140.884

Buy

MA10

142.988

Buy

MA20

140.898

Buy

MA50

141.082

Buy

MA100

135.647

Buy

MA200

126.739

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 101.44%, representing a quarter-over-quarter increase of 2.35%. The largest institutional shareholder is The Vanguard, holding a total of 9.77M shares, representing 9.79% of shares outstanding, with 1.61% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

10.08M

-6.49%

The Vanguard Group, Inc.

Star Investors

9.77M

-1.36%

Dodge & Cox

Star Investors

5.57M

+0.58%

State Street Investment Management (US)

4.47M

-8.10%

JP Morgan Asset Management

3.57M

+75.47%

T. Rowe Price Associates, Inc.

Star Investors

3.00M

+106.00%

Renaissance Technologies LLC

Star Investors

2.37M

-5.45%

Citadel Advisors LLC

2.05M

+130.48%

Wellington Management Company, LLP

2.03M

-3.29%

Geode Capital Management, L.L.C.

1.96M

-0.53%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 9.27, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.